Verve Therapeutics
Develops gene editing therapies for cardiovascular disease
About Verve Therapeutics
Verve Therapeutics focuses on developing gene editing therapies to treat cardiovascular disease. Their approach involves creating single-course treatments that aim to provide lasting solutions rather than ongoing management. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from traditional therapies that require continuous treatment. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular conditions, improving their long-term health outcomes.
Cambridge, MassachusettsHeadquarters
2018Year Founded
$353.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Hybrid Work Options
Risks
Rapid CRISPR advancements may increase competition, affecting Verve's market share.
Most CRISPR therapies are in early stages, delaying Verve's market entry and revenue.
Verve's stock drop post-offering suggests investor concerns about financial stability.
Differentiation
Verve focuses on single-course gene editing for cardiovascular diseases, unlike chronic treatments.
The company targets PCSK9 and ANGPTL3 genes, crucial for lowering blood lipid levels.
Verve's approach offers potentially curative treatments, setting it apart in the biotech sector.
Upsides
Eli Lilly's $60M investment shows confidence in Verve's cardiovascular gene editing approach.
CRISPR therapy approvals, like Casgevy, pave the way for Verve's regulatory success.
CRISPR's success in genetic blindness supports Verve's potential in cardiovascular treatments.
Funding
Total raised$353.59 M
Latest valuation$470.00 M
StageIPO
PRIVATE PLACEMENT VC
10/31/2023$148
POST IPO EQUITY
5/31/2023$60
SERIES A
5/31/2020$63
$315.00 M